In recent years, psychedelic-assisted therapy has gained a lot of attention as a possible breakthrough treatment for depression.
Substances like psilocybin, often called “magic mushrooms,” and LSD have been studied for their potential to help people who do not respond well to standard antidepressant medications. Many early studies suggested strong benefits, leading to growing excitement among scientists, doctors, and the public.
However, a new study published on March 18 in JAMA Psychiatry suggests that psychedelic therapy may not be more effective than traditional antidepressants when the comparison is made fairly.
Depression, also known as major depressive disorder, is a serious mental health condition that affects millions of people worldwide. It can cause long-lasting feelings of sadness, loss of interest, low energy, and difficulty functioning in daily life.
While antidepressant medications are commonly used, they do not work for everyone, which is why researchers have been searching for new treatment options.
Psychedelic therapy is different from traditional medication. It usually involves taking a psychedelic drug in a controlled setting with psychological support from trained therapists. Patients often report strong emotional or spiritual experiences during treatment, which may help them process difficult thoughts and feelings.
However, studying these therapies scientifically is challenging. In clinical trials, researchers usually compare a treatment to a placebo, which is an inactive substance. Ideally, participants should not know whether they are receiving the real treatment or the placebo.
This is called “blinding,” and it helps ensure that the results are not influenced by expectations.
With psychedelics, this is very difficult. Because these substances cause noticeable effects, most participants can quickly tell whether they have taken the real drug or not. This means that expectations may play a large role in how much they improve.
To address this issue, researchers from the University of California, San Francisco, UCLA, and Imperial College London designed a new type of comparison. Instead of comparing psychedelic therapy to placebo-controlled antidepressant trials, they compared it to “open-label” antidepressant trials.
In these trials, participants know they are receiving the medication, so expectations are similar between the two groups.
The researchers analyzed results from multiple studies and found something unexpected. When both treatments were compared under similar conditions, there was almost no difference in how well they worked. Patients in both groups showed similar improvements in their depression symptoms.
On average, people in both treatments improved by about 12 points on a standard depression rating scale. This means that both psychedelic therapy and traditional antidepressants helped patients, but neither appeared to be clearly better than the other.
This finding surprised the researchers. One of the lead authors, Dr. Balázs Szigeti, had expected psychedelic therapy to show stronger results. Instead, the advantage that psychedelics seemed to have in earlier studies disappeared when the comparison was made more fairly.
The researchers believe that part of the excitement around psychedelics may come from the way earlier studies were designed. In those studies, people who received psychedelics often improved much more than those who received a placebo.
However, this may be partly because participants could tell which group they were in. Those who knew they received the real drug may have felt more hopeful and engaged, while those who realized they received a placebo may have felt disappointed.
In contrast, traditional antidepressant trials often show smaller differences between treatment and placebo groups because participants are less certain about what they are taking.
When this “expectation effect” was balanced between the two types of treatment, the difference between psychedelics and antidepressants became much smaller.
This does not mean that psychedelic therapy does not work. In fact, the study shows that it can be effective. However, it suggests that its benefits may not be greater than those of existing treatments.
There are also some limitations to this study. It was based on comparing results from different trials rather than testing both treatments in the same experiment. More direct studies are needed to confirm these findings.
Even so, the research provides an important reminder. New and exciting treatments should be carefully tested to understand their true benefits. While psychedelic therapy remains a promising option, especially for people who do not respond to standard treatments, it may not be the “miracle cure” that some had hoped.
In the end, both psychedelic therapy and traditional antidepressants can help people with depression. The best choice may depend on the individual, their medical history, and their personal preferences. Future research will continue to explore how these treatments can be used safely and effectively.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more health information, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
Copyright © 2026 Knowridge Science Report. All rights reserved.
